Our Science
- IgE
- IgA
MOv18 IgE
Pipeline
Platforms
- Bispecific IgE
- IgEGs
About Us
News, Events and Publications
Careers
Contact

Epsilogen, Lonza manufacture first IgE to treat ovarian cancer

Go Back

Epsilogen and Lonza have successfully completed large-scale GMP manufacturing of MOv18 IgE, to treat platinum-resistant ovarian cancer (PROC) patients.

Waterfront,
ARC West London,
Manbre Road, Hammersmith,
London, W6 9RH

info@epsilogen.com
+44 (0)203 657 7612

Find us on Google Maps

About Us
Press Releases
Contact
Privacy Policy
Terms of Use

Epsilogen Ltd © 2026

Designed and developed by Kehorne.co.uk

We are using cookies to give you the best experience on our website.

You can find out more about which cookies we are using or switch them off in .

Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.

Strictly Necessary Cookies

Strictly Necessary Cookie should be enabled at all times so that we can save your preferences for cookie settings.

Enable or Disable Cookies Enabled Disabled

3rd Party Cookies

This website uses Google Analytics to collect anonymous information such as the number of visitors to the site, and the most popular pages.

Keeping this cookie enabled helps us to improve our website.

Enable or Disable Cookies Enabled Disabled